A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

Protocol No
ADP-0000-001-SCR
Principal Investigator
John Charlson
Phase
N/A
Summary
Perform two tests on blood and turmor tissue to test for particular types of biomarkers to see if the patient will be able to participate in the Adaptimmune Treatment Study
Description
Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: